On the heels of CAR-T cell therapy approvals by Novartis (Kymriah) and now Kite Pharma (Yescarta), the cell therapy field is gaining momentum. To keep you in the loop, we have released new coverage of industry events. Check it out and let me know what you think?
Pluristem Therapeutics Inc. (NASDAQ:PSTI) (TASE:PSTI), a leading developer of placenta-based cell therapy products, announced that the U.S. Food and Drug Administration (FDA) has granted the company an orphan drug designation for its PLX-R18 cell therapy for the prevention and treatment of acute radiation syndrome (ARS).
Be The Match BioTherapies® announced the launch of a new, implementation-ready technology platform for cell and gene therapies in clinical development or poised for commercialization. MatchSource is an ordering, tracking and delivery software for cell and gene therapies that was custom designed based on the software used by Be The Match BioTherapies’ parent company, the National Marrow Donor Program®(NMDP)/Be The Match®.
VitaMine&Yours – Combining Private Health Care and Public Donation
Vita 34 in Germany has created a combination cord blood banking product. Up until now, it was possible to store cord blood as a public donation or for private medical care. With VitaMine&Yours, Vita 34 can store cord blood as two complete and independent stem cell deposits if there is sufficient cord blood. The portion intended for personal medical care is available for individual use at all times. The second deposit is made available to the general public.
Cord Blood Banking Industry – Key Benchmarks to Track (and Why You Should Care)
Recently released, the “Complete 2017-18 Global Cord Blood Banking Industry Report” reveals key benchmarks to track and why you should care. Benchmarks are critical to assess, because the cord blood banking industry has matured substantially over the past few years, creating both serious threats and novel opportunities. Therefore, judging individual company performance relative to the broader cord blood marketplace has become substantially more complex.
Pharma Industry Accelerating Investment into Cell Therapy Companies
Without a doubt, the cell therapy industry is coming of age. One of the most telling trends within the industry is a growing interest among Big Pharma in cell therapy companies. At its core, this is a strategic way for pharmaceutical companies to diversity their product development pipeline.
While the dental stem cell storage market is an early-stage market, new competitors are quickly entering it, with the United States, UK, and India leading the way as “hot spots” for market activity. This 10-page brief identifies global competitors offering dental stem cell storage services, including company name, location, type of dental stem cell storage, and more.
Pluristem Lands $27 Million in Non-Dilutive Funding for its Advanced-Stage Cell Therapies
Non-dilutive funding, in substantial amounts, is something nearly all biotechnology companies want and few get. Although small grants from various government agencies like the NIH are helpful, Pluristem Therapeutics accomplished something unique in the last year as the recipient of three awards totaling nearly $25 million from the European Union’s Horizon 2020 program, as well as $2.4 million in smaller grants from Israel.
Ncardia to Host First Annual Applications Workshop in Cologne, Germany
Ncardia is hosting its first annual Applications Workshop (Nov. 29th-Dec. 1st) in Cologne, Germany. It includes speaker sessions followed by live demonstrations. The speakers, coming from both Pharma partners and key academia labs, will highlight the use of Ncardia's human iPSC-derived products within their field of profession. The demonstrations will show the performance of cells in applications such as MEA, contractile cell force measurement, impedance analysis and calcium transient measurement, as well as fatty acid metabolism and optogenetics.
Kite’s Yescarta™ Becomes First CAR T Therapy Approved by FDA for the Treatment of Adult Patients With Relapsed or Refractory Large B-Cell Lymphoma After Two or More Lines of Systemic Therapy
Kite, a Gilead Company, announced that the U.S. FDA granted approval to Yescarta™ (axicabtagene ciloleucel), the first chimeric antigen receptor T cell (CAR T) therapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. The list price of Yescarta in the U.S. is $373,000.
BioLife Solutions Customer Kite Pharma Receives FDA Approval for Yescarta™ CAR T-Cell Therapy
BioLife Solutions, Inc. (NASDAQ: BLFS), the leading developer, manufacturer and marketer of proprietary clinical grade cell and tissue hypothermic storage and cryopreservation freeze media, announced that its customer Kite Pharma, Inc., a wholly-owned subsidiary of Gilead Sciences, received FDA approval for Yescarta, the first CAR T-cell therapy for treatment of adult patients with relapsed or refractory large B-Cell lymphoma after two or more lines of systemic therapy.
Cell Therapy Industry Database – Featuring 140+ Cell Therapy Companies Worldwide
On the heels of CAR-T cell therapy approvals by Novartis (Kymriah) and Kite Pharma (Yescarta), this database features 140+ cell therapy companies worldwide. These are companies developing cell-based products for therapeutic use. The database was developed in-house for our own purposes, but we have had more and more clients requesting access to it. For a limited-time only, you can claim the database for only $39 and have access for life (no user license required).
Be Great,
Cade President/CEO of BioInformant.com "1st and Only Market Research Firm to Specialize in the Stem Cell Industry"
p.s. Have stem cell news to share? Hit "reply" to this email to send it to me.
|
|
|
